Li Siyu, Li Wenrui, Cheng Mengfei, Wang Xiaoxiao, Chen Wanyi
Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China.
Cardiooncology. 2025 Jul 10;11(1):66. doi: 10.1186/s40959-025-00360-3.
Anthracyclines are cornerstone chemotherapeutics, but cardiotoxicity limits their use.
This study aims to evaluate the efficacy of various drugs in preventing and treating anthracycline-induced cardiotoxicity (AIC).
We conducted an extensive search across seven databases to identify randomized controlled trials (RCTs) pertinent to the prevention and treatment of AIC with medications. Subsequently, a Bayesian Model-based network meta-analysis was performed in the R 4.4.0.
A total of 128 RCTs involving 10,431 cancer patients treated with anthracyclines and 78 drug regimens were included in this study. The network meta-analysis results showed that, compared with patients who did not receive cardioprotective drugs, those treated with Calcium Dibutyryladenosine Cyclophosphate (Mean Difference [95% Credible Interval], 8.760 [0.5917, 16.92]), Carvedilol (4.024 [0.5372, 7.656]), Carvedilol + Candesartan (7.934 [3.159, 12.91]), Compound Salvia Miltiorrhiza + Levocarnitine (9.087 [0.9160, 17.25]), Dexrazoxane (5.066 [2.589, 7.540]), Dexrazoxane + Cinobufacini (11.61 [4.590, 18.70]), Dexrazoxane + Shenqi Fuzheng (13.05 [4.640, 21.40]), Nicorandil (14.24 [5.122, 23.31]), Qiliqiangxin (11.38 [2.826, 19.91]), and Xinmai Long (6.371 [1.735, 11.02]) experienced less decrease in LVEF after chemotherapy. The SUCRA ranking results indicated that the most effective treatment option for preserving LVEF was Nicorandil (SUCRA 91.76%).
Apart from Dexrazoxane, Carvedilol, a β-blocker, also appears to show significant potential in preventing AIC. Furthermore, our results indicate that there is insufficient evidence to support the beneficial effects of statins, Sildenafil, Ivabradine, Levocarnitine, N-acetylcysteine, Glutathione, Coenzyme Q10, Vitamin E, and Vitamin C in preventing LVEF decline and exerting a positive effect on the prevention of AIC.
蒽环类药物是化疗的基石,但心脏毒性限制了它们的使用。
本研究旨在评估各种药物在预防和治疗蒽环类药物所致心脏毒性(AIC)方面的疗效。
我们在七个数据库中进行了广泛检索,以确定与药物预防和治疗AIC相关的随机对照试验(RCT)。随后,在R 4.4.0中进行了基于贝叶斯模型的网络荟萃分析。
本研究共纳入128项RCT,涉及10431例接受蒽环类药物治疗的癌症患者和78种药物方案。网络荟萃分析结果显示,与未接受心脏保护药物的患者相比,接受磷酸二丁酰环磷腺苷钙(平均差[95%可信区间]为8.760[0.5917,16.92])、卡维地洛(4.024[0.5372,7.656])、卡维地洛+坎地沙坦(7.934[3.159,12.91])、复方丹参+左卡尼汀(9.087[0.9160,17.25])、右丙亚胺(5.066[2.589,7.540])、右丙亚胺+华蟾素(11.61[4.590,18.70])、右丙亚胺+参芪扶正(13.05[4.640,21.40])、尼可地尔(14.24[5.122,23.31])启力强心(11.38[2.826,19.91])和心脉隆(6.371[1.735,11.02])治疗的患者化疗后左室射血分数(LVEF)下降较少。累积排序曲线下面积(SUCRA)排名结果表明,对保留LVEF最有效的治疗选择是尼可地尔(SUCRA 91.76%)。
除右丙亚胺外 β受体阻滞剂卡维地洛在预防AIC方面似乎也显示出显著潜力。此外,我们的结果表明,没有足够的证据支持他汀类药物、西地那非、伊伐布雷定、左卡尼汀、N-乙酰半胱氨酸、谷胱甘肽、辅酶Q10、维生素E和维生素C在预防LVEF下降及对预防AIC发挥积极作用方面的有益效果。